KYL is an EphA4 receptor tyrosine kinase inhibitor with a Kd of 0.8 µM. KYL inhibits EphA4-EphrinA5 interactions with an IC50 of 6.34 µM. Through EphA4 inhibition, KYL can prevent dendritic spine reduction, the blocking of LTP induction and neuronal apop